FI89238B - Foerfarande foer framstaellning av kompressionsbelagda tabletter - Google Patents

Foerfarande foer framstaellning av kompressionsbelagda tabletter Download PDF

Info

Publication number
FI89238B
FI89238B FI854411A FI854411A FI89238B FI 89238 B FI89238 B FI 89238B FI 854411 A FI854411 A FI 854411A FI 854411 A FI854411 A FI 854411A FI 89238 B FI89238 B FI 89238B
Authority
FI
Finland
Prior art keywords
core
process according
compression
cyclandelate
cross
Prior art date
Application number
FI854411A
Other languages
English (en)
Finnish (fi)
Other versions
FI854411A (fi
FI89238C (sv
FI854411A0 (fi
Inventor
Jan Willem Groenendaal
Gerrit Jan Sijbrands
Original Assignee
Brocades Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brocades Pharma Bv filed Critical Brocades Pharma Bv
Publication of FI854411A0 publication Critical patent/FI854411A0/fi
Publication of FI854411A publication Critical patent/FI854411A/fi
Publication of FI89238B publication Critical patent/FI89238B/fi
Application granted granted Critical
Publication of FI89238C publication Critical patent/FI89238C/sv

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Claims (8)

1. Förfarande för framställning av kompressionsbelagda tabletter, vilka innehäller en snabbt dispergerande 20 kärna, och varvid hela tabletten kan disintegrera i vatten vid 20 °C inom tre minuter till en homogen, drickbar dispersion, med en partikelstorlek av under 0. 71 mm, kännetecknat av att kärnan, som innehäller aktivämnet eller -ämnena som är utsatta för sublimation 25 och/eller omkristallisation, belägges med en ompressions-beläggning som även den är snabbt dispergerande och vil-ken innehäller en eller flera disintegrerande medel vilka väljs bland följande: a. tvärbunden polyvinylpyrrolidon 30 b. tvärbunden natriumkareboximetylcellulosa c. natriumstärkelseglykollater d. jonbytarhartser e. mikrokristallin cellulosa f. komprimerbara stärkelser 35 g. stärkelse och modifierade stärkelser h. alginsyra och derivat 1. formaldehyd-kaseiner. 14 89238
2. Förfarande enligt patentkravet 1, kännetecknat av att det disintegrerande medlet är tvärbunden polyvinylpyrro-lidon. 5
3. Förfarande enligt patentkravet 1, kännetecknat av att det disintegrerande medlet är tvärbunden karboximetylcel-lulosa.
4. Förfarande enligt patentkravet 1, kännetecknat av att 10 det disintegrerande medlet är natriumstärkelseglykollat.
5. Förfarande enligt nägot av de tidigare patentkraven, kännetecknat av att kärnan innehaller aktivt ämne eller ämnen i en koncentration som inte överstiger 70 viktpro- 15 cent.
6. Förfarande enligt patentkravet 5, kännetecknat av att kärnans aktivämne är cyklandelat. 20
7. Förfarande enligt patentkravet 6, kännetecknat av att cyklandelatet är närvarande i en dos av 400 - 1200 mg/ tablett.
8. Förfarande enligt patentkravet 7, kännetecknat av att 25 cyklandelatet är närvarande i en dos av 800 mg/tablett.
FI854411A 1984-11-13 1985-11-08 Förfarande för framställning av kompressionsbelagda tabletter FI89238C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP84201638 1984-11-13
EP84201638A EP0181966A1 (en) 1984-11-13 1984-11-13 Compression-coated dispersible tablets

Publications (4)

Publication Number Publication Date
FI854411A0 FI854411A0 (fi) 1985-11-08
FI854411A FI854411A (fi) 1986-05-14
FI89238B true FI89238B (fi) 1993-05-31
FI89238C FI89238C (sv) 1993-09-10

Family

ID=8192497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI854411A FI89238C (sv) 1984-11-13 1985-11-08 Förfarande för framställning av kompressionsbelagda tabletter

Country Status (8)

Country Link
EP (2) EP0181966A1 (sv)
JP (1) JPS61118317A (sv)
DE (1) DE3579414D1 (sv)
DK (1) DK165438C (sv)
ES (1) ES9000002A1 (sv)
FI (1) FI89238C (sv)
GR (1) GR852743B (sv)
PT (1) PT81453B (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
BR0307473A (pt) * 2002-02-07 2004-11-09 Pharmacia Corp Forma de dosagem farmacêutica para distribuição por via mucosa
WO2005051350A2 (en) * 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
WO2007052289A2 (en) * 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
WO2011111027A2 (en) 2010-03-11 2011-09-15 Dexcel Pharma Technologies Ltd. Oral dispersible delayed release tablet formulation
EP3528791B1 (en) * 2016-10-24 2023-12-06 Janssen Sciences Ireland Unlimited Company Dispersible compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96376C (sv) *
US3019169A (en) * 1958-06-23 1962-01-30 Sterling Drug Inc Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process
US3033754A (en) * 1959-12-21 1962-05-08 Lakeside Lab Inc Tablets containing hydrazine derivatives
DE1811809A1 (de) * 1968-11-29 1970-08-20 Walter Kaltschik Neue Tabletten,Kerne und Manteltabletten und Verfahren zu ihrer Herstellung
GB1601833A (en) * 1978-02-06 1981-11-04 Wellcome Found Antacid formulation
GB2067900B (en) * 1980-01-25 1983-06-22 Ddsa Pharmaceuticals Ltd Medicinal tablets

Also Published As

Publication number Publication date
EP0181650B1 (en) 1990-08-29
DK165438C (da) 1993-04-13
ES9000002A1 (es) 1989-11-16
GR852743B (sv) 1986-03-14
ES548658A0 (es) 1989-11-16
DK165438B (da) 1992-11-30
DK520685D0 (da) 1985-11-12
JPH0529205B2 (sv) 1993-04-28
FI854411A (fi) 1986-05-14
PT81453A (en) 1985-12-01
DK520685A (da) 1986-05-14
DE3579414D1 (de) 1990-10-04
JPS61118317A (ja) 1986-06-05
FI89238C (sv) 1993-09-10
EP0181650A1 (en) 1986-05-21
PT81453B (pt) 1988-01-22
FI854411A0 (fi) 1985-11-08
EP0181966A1 (en) 1986-05-28

Similar Documents

Publication Publication Date Title
RU2098093C1 (ru) Фармацевтическая композиция на основе суматриптана
RU2453306C2 (ru) Твердые оральные дозируемые формы на основе вальсартана
FI89238B (fi) Foerfarande foer framstaellning av kompressionsbelagda tabletter
AU671830B2 (en) A Pharmaceutical Preparation of Dichloromethylene Bisphosphonic Acid with Enteric Coating for Oral Use
FI101040B (sv) Förfarande för framställning av en peroralt administrerbar läkemedelsf orm för behandling av centrala dopaminbristtillstånd
KR100421347B1 (ko) 약학 혼합 제제
US20110177168A1 (en) Composition
KR20000076269A (ko) 활성 물질의 방출을 조절하기 위한 약제 조성물
JP2007224041A (ja) 医薬組成物
PT758235E (pt) Comprimido revestido com polimero compreendendo amoxicilina e clavulanato
JP2003530422A (ja) 医薬組成物
RU2153337C2 (ru) Таблетка парацетамола и домперидона с пленочным покрытием
US20080280981A1 (en) Tranexamic acid formulations
KR100846945B1 (ko) 파라세타몰을 포함하는 연하 정제
IL106743A (en) Tablets with enhanced bioavailability of claudonic acid
RU2145857C1 (ru) Противогипергликемически эффективная фармацевтическая композиция
CA2325014C (en) 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions
IE66378B1 (en) Solid oral forms of application containing ifosfamide as active substance
CA1229552A (en) Cimetidine compositions
KR20060087618A (ko) 갑상선 호르몬 약학 제제
KR20050010843A (ko) 활성 성분을 지속 방출시키는, 옥스카바제핀 함유약제학적 조성물

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: BROCADES PHARMA B. V.